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Vanilloid receptor subtype 1 (VR1) is a ligand-gated
channel that can be activated by capsaicin and other
vanilloids as well as by protons and heat. In the present
study, we have analyzed the oligomeric state of VR1.
Co-immunoprecipitation of differently tagged VR1 mol-
ecules indicated that VR1 can form oligomers. Using two
different heterologous VR1 expression systems as well
as endogenous VR1 expressed in dorsal root ganglion
cells, we analyzed oligomer formation using perfluoro-
octanoic acid polyacrylamide gel electrophoresis. Re-
sults were confirmed both with chemical cross-linking
agents as well as through endogenous cross-linking me-
diated by transglutaminase. Our results clearly show
that VR1 forms multimers in each of the expression sys-
tems with a homotetramer as a predominant form. The
oligomeric structure of VR1 may contribute to the com-
plexity of VR1 pharmacology. Finally, differences in gly-
cosylation between the systems were observed, indicat-
ing the need for caution in the use of the heterologous
expression systems for analysis of VR1 properties.
Pain-producing stimuli are detected by specialized primary
afferent neurons called nociceptors, which can be activated by
different noxious chemical (acid, irritants, inflammatory medi-
ators) or physical stimuli (heat, cold, pressure). Capsaicin, the
pungent ingredient in hot peppers, and structurally related
vanilloids such as the ultrapotent irritant resiniferatoxin
(RTX)1 bind to specific receptors on nociceptors (1–3), causing
cation influx, triggering action potentials, and inducing the
sensation of burning pain. Prolonged or repeated exposure to
capsaicin leads to pronounced tachyphylaxis and desensitiza-
tion, in which nociceptors become insensitive to capsaicin and
to other noxious stimuli. This phenomenon underlies the seem-
ingly paradoxical use of capsaicin as an analgesic agent in the
treatment of various painful disorders (4–6).
A functional vanilloid receptor termed vanilloid receptor
type 1 (VR1) has been cloned recently. Both when expressed
endogenously in cultured dorsal root ganglion cells or when
expressed heterologously in transfected human cells or frog
oocytes, VR1 can be activated by vanilloids and by noxious heat
(.43 °C) and can be activated or potentiated by protons (extra-
cellular pH ,6) (6–8). VR1 encodes a protein of 838 amino
acids with a predicted molecular mass of 92–95 kDa (9–10). It
is a nonselective cation channel with high Ca21 permeability
and belongs to the superfamily of cation channels with six
transmembrane segments including the Shaker-related volt-
age-gated K1 channels, the hyperpolarization-activated cyclic
nucleotide-gated cation channels, the cyclic nucleotide-gated
cation channels, the polycystin channels and the transient
receptor potential (Trp) family of ion channels. These proteins
all contain six transmembrane domains, a pore-forming loop
between the fifth and sixth transmembrane domains, and cy-
toplasmic C- and N-terminal domains (6, 7, 11). Within this
superfamily, VR1 is most closely related to the Trp family of ion
channels. These channels include Drosophila Trp and TrpL,
which play crucial roles in phototransduction, and the mam-
malian homologues TrpC1–7, which are candidates for store-
operated calcium channels.
Understanding of the function, gating, regulation and
quaternary structure of Trp family members is emerging rap-
idly. The Drosophila Trp and TrpL have been shown to form
heteromultimeric channels associated in a signaling complex
with a receptor (rhodopsin), an effector (phospholipase C), reg-
ulators (protein kinase C and calmodulin), and the scaffolding
protein INAD (12). Similarly, hTrp1 is localized in a caveolin-
scaffolding lipid raft domain in plasma membrane, where it
interacts directly or indirectly with a complex of Ca21 signaling
proteins such as inositol 1,4,5-trisphosphate receptor and
Gaq/11 (13). Trp3 and Trp1 form hetero-oligomers with nonse-
lective cation permeability (14, 15), and Trp4 coexpressed with
Trp1 was proposed to form store-operated calcium channels in
adrenocortical cells through homo- or heteromultimers (16).
However, their actual subunit organization has not been deter-
mined. More distant members of the superfamily, e.g. voltage-
gated K1 channels or cyclic nucleotide-gated channels, are
known to form tetramers of the same or different subunits (17).
The first direct experiments evaluating the quaternary
structure of VR1 were performed by Szallasi and Blumberg (18)
using radiation inactivation analysis. This technique, which
gives the functional size of a receptor, yielded a value for the
vanilloid receptor, detected by [3H]RTX binding, of 270 6 25
kDa; this value compares with a monomer mass for VR1 of 92
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kDa, strongly arguing for a functional size greater than the
monomer. Further evidence for oligomerization is the domi-
nant negative behavior of a mutant VR1 which does not re-
spond to capsaicin (19). Finally, a Hill-coefficient of ;2 is found
for VR1 interaction with different agonists, indicating positive
cooperativity (6, 20–22). Together with the similarities in
molecular structure between the members of the six transmem-
brane domain channel superfamily, it thus seems highly prob-
able that the active VR1 channel is composed of more than one
subunit, forming homomultimeric or heteromultimeric ion
channels (16, 23, 24). Potential partners include the VR1 ho-
mologues SIC, VRL-1, and VR5’sv (25–27). Multimeric chan-
nels could contribute to the functional heterogeneity and
complex pharmacology of VR1 seen in binding or calcium up-
take experiments in DRGs and in different heterologous
systems (28–31).
The goal of the present paper is to evaluate the native qua-
ternary structure of VR1, as the complex structure of the active
channel could provide insights into channel regulation and the
design of new analgesic agents. Using three different biochem-
ical approaches, we clearly show that the VR1 channel forms
multimers both in DRGs and in heterologous expression sys-
tems, with a tetramer as a predominant form.
EXPERIMENTAL PROCEDURES
Transfection of Cells and Cell Culture—Cos7 cells were cultured in
Dulbecco’s modified Eagle’s medium (high glucose) supplemented with
10% fetal bovine serum, 50 units/ml penicillin, and 50 mg/ml strepto-
mycin (Life Technologies, Inc.). Cos7 cells were transiently transfected
with VR1e plasmid and/or VR1eGFP plasmid using LipofectAMINE
Plus (Life Technologies, Inc.) according to the procedure recommended
by the manufacturer. VR1e and VR1eGFP plasmids were constructed as
described previously (22).
The selected stable CHO cell clone expressing pUHG102 VR1 and
pTet-Off Regulator plasmids (Tet-Off induced CHO-VR1 cells) is the
generous gift of James E. Krause and Daniel N. Cortright (Neurogen
Corp., Branford, CT). These cells were cultured in F-12 medium sup-
plemented with 10% fetal bovine serum, 50 units/ml penicillin, 50 mg/ml
streptomycin, 500 mg/ml Geneticin, 10 mM HEPES (pH 7.4) (Life Tech-
nologies, Inc.), and 5 mg/ml tetracycline (Sigma). For the optimal level
of VR1 expression the cells were cultured in tetracycline-free medium
containing 10 mM sodium butyrate (Calbiochem, San Diego, CA) for
36–48 h.
Western Blot Analysis—The cell cultures were rinsed two times with
ice-cold phosphate-buffered saline (PBS), and then cells were harvested
in ice-cold PBS containing protease inhibitors (1 tablet/10 ml of PBS)
(Roche Molecular Biochemicals), and sonicated. Protein content was
measured by a micromethod using the Bio-Rad protein assay. SDS-
PAGE was performed on a mini-slab apparatus using precast 4–12%
SDS-polyacrylamide gels (Novex, San Diego, CA) by the method of
Laemmli. Twenty mg of lysates were mixed to equal volumes of 23 SDS
sample buffer (125 mM Tris-HCl (pH 6.8), 20% glycerol, 4% SDS, 0.7 M
b-mercaptoethanol, and bromphenol blue), boiled for 5 min, and sub-
jected to SDS-PAGE, followed by electrotransfer onto nitrocellulose
membranes (Schleicher & Schuell, Keene, NH). For immunostaining,
anti-eGFP monoclonal antibody (Roche Molecular Biochemicals) was
used at 0.4 mg/ml concentration, anti-VR1 polyclonal antibody was
diluted 1:1000 and anti-PKCe polyclonal antibody (Life Technologies,
Inc.) was diluted 1:1000. The anti-VR1 polyclonal antibody was gener-
ated in rabbits against the extreme C terminus of rat VR1, namely
peptide E824-K838 (Amgen, Thousand Oaks, CA) and showed specific
recognition of VR1. Nonspecific binding of antibodies to the membranes
was blocked by a 60-min incubation with 5% milk in PBS. The mem-
branes were probed overnight at 4 °C with the different antibodies
diluted in 5% milk in PBS. Following the incubation, the membranes
were washed three times for 10 min in PBS containing 0.05% Tween 20
and then incubated for 60 min with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit IgG (Bio-Rad). After the membranes were
rinsed three times for 10 min in PBS containing 0.05% Tween 20,
immunostaining was visualized by ECL (Amersham Pharmacia Bio-
tech). BenchMark prestained Protein Ladder (Life Technologies Inc.)
was used as molecular size marker.
Co-immunoprecipitation—Plasmids encoding VR1e and VR1eGFP
were transfected into Cos7 cells either together or individually using
LipofectAMINE Plus (Life Technologies, Inc.) according to the proce-
dure recommended by the manufacturer. 48 h after transfection, 3 ml of
ice-cold radioimmune precipitation buffer without SDS (pH 7.5) con-
taining 50 mM Tris-HCl, 150 mM NaCl, 1% IGEPAL CA-630 (Sigma),
0.5% sodium deoxycholate (Sigma), and protease inhibitors (1 tablet/10
ml of PBS) (Roche Molecular Biochemicals) was added to the cells and
incubated for 10 min on ice. The lysates were centrifuged at 3,000 3 g
for 10 min to remove cellular debris. Subsequently, 10 ml of anti-PKCe
polyclonal antibody (Life Technologies, Inc.), 5 ml of anti-eGFP mono-
clonal antibody (Roche Molecular Biochemicals), or 10 ml of non-im-
mune serum was added to 1 ml of supernatant containing 0.4 mg of
protein and rotated for 4 h at 4 °C. Then, 20 ml of Protein A/G Plus-
agarose (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the
immune complexes and rotated at 4 °C overnight. The immunoprecipi-
tates were washed four times with ice-cold radioimmune precipitation
buffer without SDS, eluted with 23 SDS sample buffer, and analyzed
by Western blotting on 4–12% SDS-polyacrylamide gels.
Preparations of DRG Lysates—Cell membranes from rat DRGs were
prepared as described previously (29). Female Harlan Sprague-Dawley
rats weighting 200–250 g were decapitated under CO2 anesthesia. The
spinal columns were opened, and DRGs from all levels were collected in
ice-cold physiological saline. DRGs were homogenized in ice-cold buffer
(pH 7.4) containing 5 mM KCl, 5.8 mM NaCl, 0.75 mM CaCl2, 2 mM
MgCl2, 320 mM sucrose, and 10 mM HEPES using a tissue homogenizer
type PRO 200 (PRO Scientific Inc., Monroe, CT) followed by sonication.
Tissue homogenates were centrifuged for 10 min at 3,000 3 g (4 °C) to
remove cellular debris and the supernatant was centrifuged again for
30 min at 35,000 3 g (4 °C) to obtain a partially purified membrane
fraction (pellet). After solubilization in PBS containing 2% n-dodecyl
b-D-maltoside (Sigma), the membrane proteins were separated on PFO-
PAGE and analyzed by Western blotting.
PFO-PAGE—Proteins were fractionated by PFO-PAGE as described
by Ramjeesingh et al. (32). Freshly poured 6% Tris-glycine gels without
SDS were used. Total cell lysates were prepared from Tet-Off induced
CHO-VR1 cells 48 h after tetracycline withdrawal, from Cos7 cells
expressing VR1eGFP 48 h after transfection, and from rat DRGs as
described above. In some experiments cell lysates from CHO-VR1 cells
were treated with peptide-N-glycosidase F (New England Biolabs) for
1 h at 37 °C. Twenty mg of lysates were mixed with doubly concentrated
sample buffer (100 mM Tris base, 2–8% NaPFO (Oakwood Products
Inc., West Columbia, SC), 20% glycerol, 0.7 M b-mercaptoethanol, and
0.005% bromphenol blue, pH 8.0), the final PFO concentration being in
the range of 0.8–3.2%. After 30 min of incubation at room temperature
the samples were subjected to electrophoresis. The running buffer con-
tained 25 mM Tris, 192 mM glycine, 0.5% NaPFO, pH 8.5, adjusted with
NaOH. The electrotransfer and immunostaining were performed as
described above. As molecular weight standard, cross-linked phospho-
rylase b (Sigma) was separated on the same gels, electroblotted, and
stained with Amido Black.
Chemical Cross-linking—The following water-soluble, homobifunc-
tional N-hydroxysuccimide esters were used for protein cross-linking
studies: the non-cleavable bis[sulfosuccinimidyl]suberate (BS3) and the
base-cleavable bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone
(sulfo-BSOCOES; Pierce). Both reagents were dissolved in PBS imme-
diately before use. The lysates prepared from Tet-Off induced CHO-
VR1 cells 48 h after tetracycline withdrawal and from Cos7 cells ex-
pressing VR1eGFP 48 h after transfection were incubated with
different concentrations of cross-linkers (1 mM to 10 mM) or without any
cross-linker for 30 min at room temperature. To stop the reaction, an
equal volume of 1 M glycine was added to the mixtures and incubated for
an additional 20 min. The quenched samples were subsequently mixed
with 43 concentrated Nu-PAGE sample buffer (564 mM Tris base, 424
mM HCl, 292 mM lithium dodecyl sulfate, 2 mM EDTA, 0.7 M b-mercap-
toethanol, 0.88 mM Serva Blue G250, 0.70 mM Phenol Red, pH 8.5)
according to the description provided by the manufacturer (Novex, San
Diego, CA), incubated at 70 °C for 15 min, and then subjected to elec-
trophoresis. The samples were separated on 3–8% gradient Nu-PAGE
Tris acetate gels and analyzed by Western blotting. Cross-linking ex-
periments were also performed on living Cos7 cells transiently express-
ing VR1eGFP. The cells were incubated for 30 min at 37 °C in PBS
containing different concentrations of BS3 (0.01–10 mM) followed by
preparation of cell lysates and their Western blot analysis.
RESULTS
Co-immunoprecipitation—To determine if two or more VR1
subunits form a complex, VR1e and VR1eGFP were coex-
pressed in Cos7 cells. These differently tagged VR1 proteins
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were immunoprecipitated with anti-eGFP or anti-e tag anti-
bodies and Western blots containing the immune complexes
were probed with the reciprocal antibodies. Transfection with
just one construct as well as immunoprecipitation with non-
immune serum were used as controls. The results shown in Fig.
1 demonstrate that VR1eGFP co-immunoprecipitated with
VR1e and vice versa, suggesting the existence of at least two
VR1 molecules in a protein complex.
PFO-PAGE—The first method used to determine the nature
of the VR1 channel complex was PFO-PAGE. In this method,
PFO is used in place of SDS in gel electrophoresis, as it is less
disruptive of interactions within protein oligomers and thus
permits molecular mass determination of multimeric proteins.
VR1eGFP-transfected Cos7 cell lysates, Tet-Off induced CHO-
VR1 cell lysates, and partially purified DRG membranes were
separated on PFO-PAGE and analyzed by Western blotting
(Fig. 2). The pattern of protein migration depended on time and
temperature of incubation with sample buffer containing PFO;
a longer incubation time and higher temperature resulted in a
greater degree of subunit dissociation from the protein complex
(see Supplementary Figs. 1–6, available in the on-line version
of this article). Subunit dissociation was also highly dependent
on the ratio of PFO to protein and/or lipid (Fig. 2A). CHO-VR1
cell lysates were incubated with different PFO concentrations
(0.4–3.2%) for 30 min at room temperature and separated on
6% PFO-PAGE. Using 3.2% and 1.6% PFO, VR1 migrated as
monomers and some dimers. With 0.8% PFO, VR1 was sepa-
rated into multiple bands representing VR1 monomers, dimers,
trimers, and tetramers; using 0.4% PFO, VR1 migrated mainly
as tetramer, but higher molecular weight protein aggregates
were also seen, probably due to insufficient solubilization of
membrane proteins (Fig. 2A). Based on these results in each
system, we varied the PFO concentration to find the appropri-
ate conditions for detecting oligomers.
In CHO-VR1 cells VR1 monomer is present in two different
forms: a non-glycosylated form with apparent molecular mass
of 95 kDa and a glycosylated form with calculated molecular
mass of 114 kDa as shown in Fig. 2 (A, B, and F). Treatment for
1 h at 37 °C with peptide-N-glycosidase F, an enzyme that
cleaves N-glycosidic bonds between the sugar portion and as-
paragine of glycoproteins, reduced or eliminated the upper
band of VR1 monomer representing the glycosylated form of
the protein. On SDS-PAGE, VR1 migrated as a double band
without and as a single band after PNGase F treatment (Fig.
2F). On PFO-PAGE the upper band of VR1 monomer and some
upper bands of the dimers and trimers were markedly reduced
with PNGase F treatment, and there also was a shift in the
mobility of VR1 tetramer (Fig. 2B). Based on these observa-
tions, we assume that the multiple bands corresponding to VR1
multimers are due to the different combinations of the glyco-
sylated and non-glycosylated monomers, with predicted appar-
ent molecular masses ranging from 190 to 220 kDa for dimers
(three possible bands of 190, 205, and 220 kDa) and from 285 to
330 kDa for trimers (four possible bands of 285, 300, 315, and
330 kDa). The failure to resolve multiple bands of VR1 tetram-
ers (five possible bands with predicted apparent molecular
masses of 380, 395, 410, 425, and 440 kDa) can be explained by
the decreased resolution of the gel in the higher molecular
weight region; the increased mobility of VR1 tetramer after
glycosidase treatment is still apparent. In the treated sample,
a band with higher molecular mass and some protein aggre-
gates stacked at the top of the separating gel are also seen.
Based on our present studies, their nature and importance
cannot be determined.
In the other heterologous system used, VR1eGFP migrated
as four distinct bands on 6% PFO gels (Fig. 2C) with estimated
molecular masses of 119, 236, 345, and 464 kDa, respectively
(Fig. 2D). Molecular mass determination of the observed pro-
tein species was based on the linear relationship of the loga-
rithm of the molecular masses of cross-linked phosphorylase b
subunits used as molecular weight standards versus their mi-
gration distance. Based on the obtained molecular weights, we
assume that these four bands represent the VR1eGFP mono-
mers, dimers, trimers, and tetramers (predicted molecular
mass for VR1eGFP of 124, 248, 372, and 496 kDa). VR1eGFP
migrated as a single band on SDS-PAGE as shown on Fig. 2F,
although some glycosylation (10–15%) was seen in some exper-
iments, resulting in the appearance of a double band when
higher exposure times were used for ECL development.
After treating the cells expressing VR1eGFP for 30 min with
the VR1 agonist RTX at doses activating the channel,
VR1eGFP was separated as monomer, dimer, trimer, and tet-
ramer on PFO-PAGE (Fig. 2C) and as monomer, dimer, and
multimer on SDS-PAGE (Fig. 3A), showing that some covalent
bonds are formed between the subunits of the complex. Some
higher molecular weight bands running in the PFO-stacking
gels could be visualized with higher exposure times (see sup-
plemental material, available on line) possibly because some
other proteins or another preformed complex are covalently
cross-linked to VR1 tetramer.
When partially purified DRG membranes were subjected to
PFO-PAGE using optimized conditions (solubilization of mem-
brane proteins with 2% n-dodecyl b-D-maltoside and incubation
with sample buffer containing PFO at a final concentration of
0.8% for 30 min room temperature), VR1 migrated as a major
band representing VR1 tetramer and as a minor band
representing VR1 monomer (Fig. 2E). When higher PFO con-
centrations were used, VR1 monomers, dimers, trimers, and
tetramers could be also seen (see supplemental material, avail-
able on line). VR1 monomer migrated as a single band both on
PFO and SDS-PAGE showing the lack of the glycosylated form
of VR1 in DRG (Fig. 2, E and F). In accordance with this
observation, VR1 tetramer from DRG had a slightly higher
mobility than the VR1 tetramer from CHO-VR1 cells, as the
tetramer of the latter is a combination of the glycosylated and
non-glycosylated form of VR1 resulting in a complex with
higher molecular weight.
Endogenous Cross-linking of VR1 by Transglutaminases
FIG. 1. Co-immunoprecipitation of VR1e and VR1eGFP. Plas-
mids encoding VR1e and VR1eGFP were transfected into Cos7 cells
either together or individually. Cell lysates were processed for Western
analysis or used for immunoprecipitation. The result shown is from one
of two independently performed experiments. A, cell lysates were im-
munoprecipitated with anti-PKCe polyclonal antibodies (IP-PKCe) or
non-immune serum (IP-NIS) and Western blots of total cell lysates
(lysate), and the immune complexes were probed with anti-eGFP anti-
bodies. B, cell lysates were immunoprecipitated with anti-eGFP mono-
clonal antibodies (IP-eGFP) or non-immune serum (IP-NIS) and West-
ern blots of total cell lysates (lysate) and the immune complexes were
probed with anti-PKCe antibodies.
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upon Vanilloid Treatment of Cells—Upon VR1 activation by
agonists such as capsaicin or its ultrapotent analog RTX, VR1
became covalently cross-linked as detected by SDS-PAGE. The
cross-linking depended on time, on ligand concentration, and
on the presence of extracellular calcium. Treatment of Cos7
cells expressing VR1eGFP with different doses of RTX (0.001–1
nM) for 30–60 min resulted in formation of VR1 dimers and
multimers; the cross-linking was not seen when 1 mM EGTA
was added to the extracellular fluid (Fig. 3A). The lowest RTX
concentration causing cross-linking was 0.01 nM. This ligand
concentration is sufficient to activate the channel and induce a
sustained increase in intracellular Ca21 concentration (see
supplemental information, available on line). Cross-linked
VR1eGFP showed a pattern similar to control VR1eGFP with-
out agonist treatment when separated on PFO-PAGE (Fig. 2C).
The same multimerization was observed when cells were
treated with other VR1 agonists (capsaicin, olvanil, PPAHV) at
doses known to activate the VR1 channel but was not observed
with the competitive inhibitor capsazepine at concentrations
up to 30 mM. Likewise, pretreatment with 10 mM capsazepine
could prevent the covalent bond formation between VR1 mono-
mers (Fig. 3B). Treatment of cells with 1–10 mM ionomycin, an
agent that increases intracellular Ca21, did not result in the
same degree of cross-linking, although some formation of
dimers and a very low amount of higher oligomers could be
seen (see supplemental information, available on line). We
surmise that covalent cross-linking of VR1 reflects the Ca21-
dependent activation of endogenous transglutaminases. Con-
sistent with this interpretation, pretreatment with 20 mM
cysteamine or 250 mM mono-dansylcadaverine, two transglu-
taminase inhibitors, prevented the covalent cross-linking (Fig.
3B). Similar cross-linking of VR1 in response to VR1 agonists
FIG. 2. Determination of VR1 oligomeric structure using PFO-PAGE. Total cell lysates prepared from VR1eGFP-transfected Cos7 cells,
Tet-Off induced CHO-VR1 cells treated or not with PNGase F, and partially purified DRG membranes solubilized with 2% n-dodecyl b-D-maltoside
were separated on 6% PFO-PAGE, electrotransferred to nitrocellulose membranes, and immunostained with appropriate antibody. In parallel,
cross-linked phosphorylase b was separated on the same gel, electrotransferred, and visualized by Amido Black staining for molecular weight
determination purposes. These results are representative of at least three independent experiments. A, CHO-VR1 lysates were incubated with
sample buffer containing different PFO concentrations for 30 min at room temperature before electrophoresis; the Western blot was probed using
anti-VR1 antibody. B, CHO-VR1 cell lysates were treated or not with peptide-N-glycosidase F for 1 h at 37 °C; the Western blot was probed using
anti-VR1 antibody. C, separation of VR1eGFP (with or without agonist activation) on 6% PFO gel. Anti-eGFP monoclonal antibody was used for
probing. D, the molecular weights of the different VR1eGFP protein species were calculated using the linear relationship between the distance of
migration (x axis) and the logarithm of molecular weight (y axis) of cross-linked phosphorylase b. E, separation of VR1 from DRG and CHO-VR1
on 6% PFO-PAGE; anti-VR1 antibody was used for probing. F, separation of VR1eGFP, and VR1 from induced CHO cells and DRG on 4–12%
SDS-PAGE. Anti-eGFP monoclonal and anti-VR1 polyclonal antibody were used for probing.
Subunit Structure of Capsaicin Receptor28616
was seen in CHO-VR1 cells as well (see supplemental informa-
tion, available on line).
Chemical Cross-linking—A third method to explore VR1 oli-
gomerization and to potentially reveal associated proteins in
complex with VR1 was cross-linking with chemical cross-link-
ing agents. Two water-soluble cross-linkers were examined in
detail: the non-cleavable cross-linker BS3 with a spacer arm of
1.14 nm and the base-cleavable cross-linker sulfo-BSOCOES
with a spacer arm of 1.3 nm. Total cell lysates from VR1eGFP-
transfected Cos7 cells and from induced CHO-VR1 cells,
treated or not treated with PNGase F, were incubated with
different concentrations of the cross-linkers for different times
at room temperature. The formed complexes were separated on
Nu-PAGE Tris acetate gels for better separation of high molec-
ular protein complexes and were analyzed by Western blotting.
Fig. 4 (A and B) shows the immunoblot of the reaction products
when different concentrations of BS3 were used as cross-linkers
with a 30-min incubation time at room temperature. As shown
in Fig. 4A, the amount of VR1eGFP monomers decreased with
increasing concentration of BS3, whereas the amount of the
oligomeric forms increased concomitantly; first dimers, then
trimers and tetramers were formed. Incubation with 300 mM
BS3 resulted in formation of VR1eGFP dimers, trimers, and
tetramers, but no other protein species of intermediate molec-
ular weights, indicating the presence of other proteins in the
VR1 complex, were found in this system. At higher cross-linker
concentrations, multimers with calculated molecular weights
corresponding to VR1 hexamers were also formed. When the
cross-linking experiments were performed on CHO-VR1 cell
lysates, a more complex pattern of protein separation was seen,
partly because dimers, trimers, and tetramers with different
molecular weights can be formed from glycosylated and non-
glycosylated VR1 monomers. To prevent this phenomenon,
PNGase F-treated VR1 was used. Using different BS3 concen-
trations up to 1 mM, formation of VR1 dimers, trimers, and
tetramers was seen (Fig. 4B). At higher cross-linker concentra-
tions, multimers with calculated molecular weights corre-
sponding to VR1 hexamers and octamers were also formed. The
molecular weight determination of the higher molecular weight
complexes is problematic, however, because of the decreased
resolution of Nu-PAGE in this range as well as the lack of good
high molecular weight markers. When sulfo-BSOCOES was
used as a cross-linker, similar cross-linking patterns were ob-
served, although sulfo-BSOCOES was somewhat less efficient
than was BS3 (see supplemental information, available on
line).
Cross-linking experiments were also performed on living
Cos7 cells expressing VR1eGFP, when the chemical cross-
linker can form covalent bonds only between accessible pri-
mary amines sitting on the outer surface of cell membranes.
The cells were incubated with different concentrations of BS3
for 30 min at 37 °C; cell lysates were prepared and analyzed by
Western blotting. As shown on Fig. 4C, at higher BS3 concen-
trations (1–10 mM), VR1eGFP migrated as four sets of bands
representing monomers, dimers, trimers, and tetramers with-
out any other, intermediate molecular weight or high molecu-
lar weight complexes being present except some highly cross-
linked polymers not able to enter the gel. The VR1eGFP dimers
run as double or multiple bands; we assume that dimers are
formed between the glycosylated and non-glycosylated forms of
VR1eGFP, which can be observed with the higher exposure
times needed to visualize trimers and tetramers present at
lower amount.
DISCUSSION
Analysis of the native, multimeric structure of membrane
proteins is problematic. SDS-PAGE, although a powerful tech-
nique for determination of monomer molecular weights, dis-
rupts protein-protein interactions. Sucrose density gradient
centrifugation and gel filtration after solubilization of mem-
brane complexes with relatively mild detergents can be used,
assuming that adequate conditions for solubilization can be
established (32–34); however, these methods require large
amounts of recombinant or purified proteins and lack the re-
solving power of PAGE.
To evaluate the quaternary structure of VR1, we used three
different approaches. First, we coexpressed two differently
tagged versions of VR1 in Cos7 cells. Immunoprecipitation of
either caused co-immunoprecipitation of the other, implying
the presence of at least two subunits of VR1 in the receptor
complex. These results complement the findings of Oxford et al.
(19), who demonstrated that a mutant of VR1 could have dom-
inant negative activity on channel function.
To characterize the composition of the VR1 receptor complex,
we used PFO-PAGE, a novel method for quaternary structure
determination of membrane proteins (32). We analyzed VR1 in
two different heterologous expression systems, Cos7 cells tran-
siently expressing VR1eGFP and a Tet-Off inducible CHO-VR1
cell line, and we examined native VR1 in rat dorsal root gan-
glion membranes. In the two heterologous systems, we detected
VR1 monomers, dimers, trimers, and tetramers, although by
lowering the PFO concentration we were able to decrease the
relative ratio of the lower oligomers and find conditions where
tetramer was the major form of VR1. In each system the opti-
mal protein/PFO ratio had to be determined to yield a PFO
percentage that did not result in disaggregation of subunits
from the protein complex but did give adequate solubilization.
FIG. 3. Cross-linking of VR1 by transglutaminase upon VR1
channel activation. Cos7 cells expressing VR1eGFP were treated
with different doses of RTX for 30 min in the absence or presence of 1
mM EGTA, or after pretreatment with the competitive VR1 antagonist
capsazepine or inhibitors of transglutaminase. The total cell lysates
were analyzed on 4–12% SDS-PAGE, followed by electrotransfer and
immunostaining with anti-eGFP monoclonal antibodies. Similar results
were obtained in three to five independent experiments for each agent.
A, immunoblot of cross-linked VR1 upon treatment with different doses
of RTX in the absence or presence of EGTA. B, 1-h pretreatment with
capsazepine (10 mM), with cysteamine (20 mM) or with mono-dansylca-
daverine (250 mM) prevented the formation of VR1 multimers in re-
sponse to 0.1 nM RTX treatment.
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When partially purified DRG membranes were analyzed by
PFO-PAGE using optimized conditions, VR1 was present
mainly as tetramer and some monomer but without evident
dimers, trimers, or higher molecular weight protein aggregates
being present, although at higher PFO concentrations the oli-
gomers smaller than tetramer became detectable. VR1 in DRG
was non-glycosylated in contrast to VR1 in CHO cells, which
were highly glycosylated (; 60%). We cannot distinguish
whether the existence of oligomers smaller than the tetramers
represent artifacts of disaggregation by the PFO or are present
in the native membranes. Kir 2.1, an inwardly rectifying po-
tassium channel known to exist as tetramers in membranes,
was shown to migrate as a single band with a molecular weight
corresponding to the tetramer on PFO-PAGE. On the other
hand, the GABA-A receptor complex, which is thought to be a
heteropentameric oligomer formed from three different sub-
units, was found to migrate as trimers and pentamers on PFO-
PAGE, the trimeric form being the predominant band (32). We
conclude that VR1 is indeed a multimer, most possibly a ho-
motetramer. We observe modest differences in post-transla-
tional modification between native VR1 and VR1 expressed in
heterologous systems, just as somewhat different behavior of
endogenous and heterologously expressed VR1 has been seen
in calcium uptake, binding, and other experiments (28–31).
These differences emphasize the need for caution in interpre-
tation of results using heterologous expression systems.
In the course of our studies, we found that VR1 becomes
covalently cross-linked spontaneously in the presence of VR1
agonists. The pattern of cross-linking, which was analyzed
mostly by SDS-PAGE, was similar to that found for VR1 by
PFO-PAGE in the absence of agonists, namely multimers up to
tetramer and, to a much lower extent, some higher polymers
but with no bands indicative of the formation of hetero-oli-
gomers between VR1 and protein subunits of a different size.
The VR1 agonist dependence, the inhibition by the VR1 com-
petitive antagonist capsazepine, and the inhibition in the ab-
sence of extracellular calcium all fit with the model that the
covalent cross-linking reflects elevated intracellular calcium in
response to VR1 activation. The probable mechanism respon-
sible to this protein cross-linking is through transglutaminase,
since pretreatment of the cells with known transglutaminase
inhibitors could prevent VR1 oligomerization. Transglutami-
nases are a family of structurally and functionally related
Ca21-dependent enzymes that catalyze cross-linking reactions
of proteins by transferring the g-carboxy group from protein-
bound glutamine to the e-amino group of protein-bound lysine
residues or other primary amines (35, 36). The cross-linking of
proteins by transglutaminases has been shown to play a vari-
ety of physiologically important functions in different systems.
For example, transglutaminases are involved in cross-linking
of cornified envelope proteins during terminal differentiation of
keratinocytes (36–39) and in programmed cell death (40, 41).
In the current study, we have explored the endogenous cross-
linking of VR1 as a reporter for its state of association. Studies
are in progress to evaluate its possible contribution to VR1
desensitization or DRG toxicity in response to vanilloid
treatment.
Our third approach to characterize VR1 subunit structure
was to use chemical cross-linking agents. This method has been
widely used in the nearest neighbor analysis of membrane
proteins. The bifunctional chemical cross-linkers used in the
present study produce covalent bonds between primary amines
FIG. 4. Chemical cross-linking of
VR1 by BS3. Total cell lysates of Cos7
cells expressing VR1eGFP and of induced
CHO-VR1 cells treated or not with
PNGase F were incubated with different
concentrations of BS3 (1 mM-10 mM) for 30
min at room temperature. After quench-
ing the reaction, the cross-linked proteins
were separated on 3–8% Nu-PAGE, elec-
troblotted, and immunostained with ap-
propriate antibodies. In living cell exper-
iments, Cos7 cells expressing VR1eGFP
were treated with different concentra-
tions of BS3 for 30 min at 37 °C followed
by Western blot analysis of the lysates.
The molecular mass of the protein com-
plexes was determined by cross-linked
phosphorylase b separated on the same
gels, electroblotted and stained with
Amido Black and by SeeBlue pre-stained
protein standard. A and B are from a rep-
resentative experiment repeated an addi-
tional two times; the experiment illus-
trated in C was repeated once with
similar results. A, BS3 cross-linked
VR1eGFP probed with anti-eGFP mono-
clonal antibody (asterisks indicate oli-
gomers higher than tetramer). B, BS3
cross-linked CHO-VR1 after PNGase F
treatment probed with anti-VR1 poly-
clonal antibody (asterisks indicate hexam-
ers and octamers). C, cross-linking exper-
iments on living cells. The Western blot
was probed with anti-eGFP monoclonal
antibody.
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of proteins resulting in intra- or intermolecular cross-linking.
The cross-linked oligomers subsequently can be separated on
SDS-PAGE and their structures deduced from the sizes of the
complexes. This technique has helped demonstrate the hexam-
eric nature of bacterophage T7 primase/helicase (42), the oli-
gomeric structure of human immunodeficiency virus-1 reverse
transcriptase (43), and the stoichiometry of subunits in the
native atrial G-protein-gated K1 channel, IKACh (44). Using
BS3 or sulfo-BSOCOES, a non-cleavable or a base-cleavable
water soluble cross-linking agent, we have found that
VR1eGFP expressed in Cos7 cells can be cross-linked to form
dimers, trimers, and tetramers, as well as higher molecular
weight polymers. We did not observe other associated proteins.
The higher molecular weight polymers (more than tetramer)
were not observed when the cross-linking experiments were
performed on living cells, conditions where the water-soluble
agents can form covalent bonds only between the accessible
primary amines sitting on the outer surface of cell membranes.
In CHO-VR1 cells the same pattern of oligomerization was
found, but occasionally some bands with intermediate molecu-
lar weight were also seen, albeit at a much lower level. This
suggests the possibility that proteins can be associated with
VR1. The Drosophila Trp and TrpL proteins are known to be
associated with proteins such as phospholipase C or protein
kinase C via the scaffolding protein INAD (12). Likewise,
hTRP1 was shown to be associated with G-proteins and caveo-
lin (13). On the other hand, some other members of the super-
family are known to form homo- or heterotetramers without
being in tight complexes with other proteins (17, 44). An unre-
solved issue is the origin of the bands with mobilities corre-
sponding to a hexamer or octamer. Based on the expectation of
a tetrameric structure, we surmise that we have cross-linked
subunits of adjacent tetrameric channels. Drosophila Trp and
TrpL proteins are known to be clustered in multichannel com-
plexes (12). In any case, the role of such clustering in the
regulation of VR1 and its pharmacology remains to be assessed.
In summary, the experiments presented here using multiple
independent methods demonstrate that the VR1 channel is a
multimer and that the VR1 channel is most likely made up of
four identical subunits. Variation in the individual subunits of
the tetramer, whether through splice variants or through post-
translational modification, could provide a mechanism to gen-
erate complexity.
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